Migraine and Cardiovascular Disease: Understanding the Link and Reducing Risk

Epidemiological Associations

  • Migraine with aura: 2× increased risk of ischemic stroke (especially women <45, smokers, oral contraceptive users).
  • Migraine (overall): Modestly increased risk of myocardial infarction, angina, coronary revascularization, and cardiovascular mortality.
  • Shared risk factors: Hypertension, hyperlipidemia, obesity, insulin resistance, smoking, patent foramen ovale (PFO) more common in migraine with aura.

Potential Pathophysiological Mechanisms

  • Endothelial dysfunction: Migraineurs show impaired flow-mediated dilation, increased arterial stiffness.
  • Inflammation: Elevated CRP, cytokines during and between attacks; promotes atherosclerosis.
  • Autonomic dysregulation: Sympathetic overdrive, reduced heart rate variability.
  • Cortical spreading depression (CSD): May trigger pro-thrombotic state, microvascular injury.
  • Genetic overlap: Shared loci (e.g., PHACTR1, MMP16) for migraine and CVD.
  • Medication effects: Ergotamines, triptans (vasoconstriction); NSAIDs (CV risk); oral contraceptives (thrombosis).

Stroke Risk Nuances

  • Absolute risk remains low in young women without other risk factors.
  • Highest risk: Migraine with aura + smoking + combined oral contraceptive (COC) = synergistic.
  • Migrainous infarction (stroke during aura) is rare (<1% of ischemic strokes in young women).

Cardiovascular Risk Reduction for Migraine Patients

  1. Vascular risk assessment: Lipid panel, HbA1c, BP, BMI, smoking status, family history—at migraine diagnosis and periodically.
  2. Contraception counseling: Avoid estrogen-containing COCs in migraine with aura. Progestin-only (pill, IUD, implant) preferred.
  3. Smoking cessation: Single most impactful modifiable factor.
  4. Blood pressure control: Target <130/80; avoid beta-blockers if contraindicated, but they can double as migraine preventive.
  5. Lipid management: Statin if indicated per ASCVD risk calculator.
  6. Weight management & exercise: 150 min/week moderate activity.
  7. Medication review: Limit triptan/ergot use if high CV risk; avoid in established CVD. Consider gepants (ubrogepant, rimegepant) or lasmiditan (no vasoconstriction).
  8. PFO closure: Not routinely recommended for migraine alone; only per stroke guidelines (RoPE score, multidisciplinary team).

Collaborative Care

Neurologist + primary care + cardiology coordination ensures migraine treatment doesn't compromise cardiovascular health, and vice versa. Shared decision-making is essential.

Migraine - Related Articles